Entering the New Zealand pharmaceutical market.

New Zealand’s pharmaceutical sector operates within a regulatory framework and a distinctive public funding model that shapes how products are brought to market. Foreign companies, local businesses expanding into pharmaceutical distribution or manufacturing, and investors assessing the sector all face the same core challenge: understanding how the regulatory, commercial and structural requirements fit together before committing to a market entry path.

This guide explains how the New Zealand pharmaceutical market works, how Medsafe registration and Pharmac’s funding model affect your strategy and what business setup and ongoing compliance look like in practice.

Overview of the New Zealand pharmaceutical market

New Zealand’s pharmaceutical market spans prescription medicines, over-the-counter (OTC) products, generics, biologics and medical devices. Prescription medicines make up the majority of the regulated market, with generics playing an increasingly significant role as Pharmac’s funding decisions favour cost-effective alternatives. The medical devices segment is regulated separately under a different Medsafe framework.

For international companies, New Zealand is often considered alongside Australia as part of a combined entry strategy. The Australia-New Zealand Closer Economic Relations (CER) agreement and the regulatory alignment between Medsafe and the TGA mean that approval processes and commercial structures in the two markets are more compatible than in most other pairs of countries. Companies that have already navigated the Australian regulatory environment tend to find the New Zealand pathway more predictable as a result.

How pharmaceutical regulation works in New Zealand

Medsafe, part of the Ministry of Health, is responsible for regulating medicines, medical devices and related products in New Zealand. Its primary role is to assess and approve products for sale, monitor safety and quality, and maintain the New Zealand Register of Therapeutic Products.

The medicines approval pathway

To sell a prescription or pharmacist-only medicine in New Zealand, a company or sponsor must obtain consent to distribute (CTD) from Medsafe. The process involves submitting a medicine application that includes clinical data, manufacturing information and labelling details. Medsafe evaluates applications against safety, efficacy and quality standards aligned with international frameworks.

The timeline for a standard application is typically 12 to 18 months, though this varies depending on the complexity of the dossier and whether the product falls into an expedited category. Products with unmet clinical need or serious disease indications may qualify for provisional consent, which allows earlier access under specific conditions.

TGA alignment and the recognition pathway

One of the most practical features of the New Zealand regulatory environment is the formal alignment with Australia’s TGA. Under the established recognition pathway, medicines already approved by the TGA can be assessed through an abbreviated process in New Zealand. This does not mean automatic approval, but it substantially reduces the data requirements and can compress review timelines.

Medsafe also recognises approvals from a range of other reference agencies, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and Health Canada. For products with existing approvals from these bodies, the New Zealand application process is generally more streamlined than a full independent assessment.

Who can hold a consent to distribute?

The consent to distribute is issued to a New Zealand-based sponsor, not directly to the overseas manufacturer. This means foreign companies entering the market need either to establish a New Zealand legal entity that can act as a sponsor, or to appoint a local third-party sponsor to hold the consent on their behalf. The choice between these two models has implications for control, commercial flexibility and ongoing compliance responsibility.

Pharmac and the public reimbursement pathway

Pharmac (the Pharmaceutical Management Agency) is the New Zealand government agency responsible for deciding which medicines are publicly funded and at what price. It operates a single national formulary, the New Zealand Pharmaceutical Schedule, and negotiates supply agreements directly with suppliers. This centralised model is uncommon globally and has a significant effect on how pharmaceutical companies plan their commercial strategy in New Zealand.

How Pharmac makes funding decisions

Pharmac evaluates funding applications using a framework that weighs clinical benefit, cost-effectiveness, budget impact and the needs of the New Zealand population. The process is transparent but competitive: companies submit applications, Pharmac assesses them against other funding priorities and decisions are made through a structured prioritisation process. Funding is not guaranteed simply because a product is approved by Medsafe.

Pharmac also uses reference pricing and cross-class comparisons to keep funded medicine costs down. This means that the price a company receives for a publicly funded product is often substantially lower than in comparable markets. For some products, particularly generics and biosimilars, Pharmac uses sole-supply tendering, which can exclude competitors entirely if they are not successful tenderers.

Funded versus unfunded markets

A medicine can be Medsafe-approved but not Pharmac-funded. In that case, patients pay the full cost out of pocket, or through private health insurance. For some product categories, particularly newer specialty medicines or those without strong cost-effectiveness data relative to existing treatments, the unfunded private market may be the more realistic commercial pathway, at least initially.

Companies entering New Zealand should assess both pathways separately. The funded market offers volume and stability but at compressed margins. The unfunded market offers higher per-unit returns but requires a different commercial infrastructure and a realistic view of patient access and willingness to pay.

How long does the Pharmac process take?

The timeline from application to funding decision varies widely. Simple applications with strong comparative data and low budget impact can move through in 12 to 24 months. Complex or high-cost applications, particularly for specialty medicines, can take considerably longer. Pharmac publishes its assessment queue and meeting schedules, which gives some visibility into expected timelines.

Business setup and market entry structures

The choice of market entry structure affects regulatory responsibility, tax exposure, governance requirements and how much operational control a foreign parent retains over its New Zealand activities. There is no single correct model, and the right approach depends on the company’s product type, commercial objectives and longer-term plans for the market.

New Zealand subsidiary

Registering a New Zealand limited liability company is the most common structure for foreign pharmaceutical companies entering the market with a direct commercial presence. A subsidiary is a separate legal entity, which limits liability for the parent and creates a clear local identity for regulatory and contractual purposes.

Under the Companies Act 1993, at least one director of a New Zealand company must be resident in New Zealand or in Australia (where the company also has an Australian director). For overseas-owned companies, this requirement is a common compliance consideration that needs to be planned for early. Acclime provides experienced local directors who understand both the regulatory environment and the practical realities of operating in the market.

Branch registration

An overseas company can also register a branch in New Zealand, which allows it to operate in the country without creating a separate legal entity. A branch is an extension of the parent company rather than an independent entity, which means the parent carries the legal and financial obligations directly. Branch registration is sometimes used by companies that want a lighter initial footprint or that are testing market conditions before committing to a full subsidiary structure.

Distributor and sponsor arrangements

For companies that do not want to establish their own New Zealand entity immediately, appointing a local distributor or licensed sponsor is a viable entry path. Under this model, the New Zealand-based distributor holds the consent to distribute and manages local regulatory compliance, while the foreign company retains manufacturing and supply chain control. This approach reduces the initial setup burden but limits commercial flexibility and visibility in the market.

WAND registration and ongoing compliance

Companies involved in importing, distributing or wholesaling medicines in New Zealand need to comply with Medsafe’s WAND requirements. These set out the standards for premises, storage, documentation, record-keeping and quality systems that wholesale distributors are expected to maintain. Registration under WAND is not a one-time approval: companies are subject to periodic audits and are required to keep their records current and accurate.

Acclime assists with the full WAND process, including initial registrations, product and sponsor set-up, record updates and ongoing maintenance. The focus is on ensuring records remain accurate, current and aligned with New Zealand regulatory requirements, which reduces the risk of delays, errors or issues during audits or compliance reviews.

Getting to market: a practical sequence

Market entry in the pharmaceutical sector is rarely linear, but the following sequence reflects the typical progression for a foreign company establishing a regulated presence in New Zealand.

Timelines vary considerably depending on the product, the entry structure and whether recognition pathways apply. A realistic planning horizon from initial assessment to first commercial sale is 18 to 36 months for a prescription medicine entering through the standard pathway.

Conclusion

New Zealand’s pharmaceutical market rewards companies that understand its specific regulatory logic before they commit to an entry path. The Medsafe framework, Pharmac’s funding model and the compliance requirements around distribution and governance all operate differently from larger markets, and the decisions made at the setup stage have a direct bearing on both speed to market and longer-term operating efficiency.

In practical terms, that means confirming your product’s regulatory status and recognition pathway, assessing the funded and unfunded market options separately, choosing the right legal structure for your situation and building a compliance framework that can sustain ongoing obligations. For companies that have already navigated the Australian TGA, the New Zealand pathway offers meaningful efficiencies, but it still requires local knowledge and local presence to execute well.

How Acclime can help with pharmaceutical market entry in New Zealand

Acclime provides end-to-end support for overseas pharmaceutical manufacturers, medical product distributors and life sciences companies entering or expanding within New Zealand. Our services cover company registration and resident director appointments, Medsafe WAND registration and ongoing record management, annual statutory filings, financial statement preparation, tax and GST compliance, and broader governance support.

By working with Acclime, your offshore team gets a single point of contact on the ground who understands both the regulatory environment and the commercial realities of operating in the New Zealand market. Contact us to discuss your market entry plans and get a clear view of what is required and where we can assist.